Search
01/03/2023
Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial
Waters, L, Assoumou, L, Gonzalez-Cordon, A, Rusconi, S, Domingo, P, Gompels, M, de Wit, S, Raffi, F, Stephan, C, Masia, M, Rockstroh, J, Katlama, C, Behrens, GMN, Moyle, G, Johnson, M, Fox, J, Stellbrink, HJ, Guaraldi, G, Florence, E, Esser, S, Gatell, JM, Pozniak, A, Martinez, E. Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial. CLINICAL INFECTIOUS DISEASES. 2023; 76(5)DOI:10.1093/cid/ciac827. PMID:36259527. IF:8.200(Q1/1D).
01/03/2023
T22-PE24-H6 Nanotoxin Selectively Kills CXCR4-High Expressing AML Patient Cells In Vitro and Potently Blocks Dissemination In Vivo
Nunez, Y, Garcia-Leon, A, Falgas, A, Serna, N, Sanchez-Garcia, L, Garrido, A, Sierra, J, Gallardo, A, Unzueta, U, Vazquez, E, Villaverde, A, Mangues, R, Casanova, I. T22-PE24-H6 Nanotoxin Selectively Kills CXCR4-High Expressing AML Patient Cells In Vitro and Potently Blocks Dissemination In Vivo. Pharmaceutics. 2023; 15(3)DOI:10.3390/pharmaceutics15030727. PMID:36986589. IF:4.900(Q1/2D).
01/03/2023
Quantitative PCR for the Diagnosis of HCMV Pneumonia in HSCT Recipients and Other Immunocompromised Hosts
Berengua, C, Martino, R. Quantitative PCR for the Diagnosis of HCMV Pneumonia in HSCT Recipients and Other Immunocompromised Hosts. Hemato. 2023; 4(1)DOI:10.3390/hemato4010008. PMID:. IF:(Q/D).
01/03/2023
Treatment of hypertriglyceridaemia with icosapent ethyl in patients with high/very high cardiovascular risk. Consensus document of the Sociedad Española de Cardiología [Spanish Society of Cardiology] and the Sociedad Española de Diabetes [Spanish Diabetes Society].
Pedro-Botet J, Barrios V, Sánchez-Margalet V, Tamargo J, Arrieta F, Gámez JM, Gimeno-Orna JA, Escobar C, Gómez-Doblas JJ, Pérez A. Treatment of hypertriglyceridaemia with icosapent ethyl in patients with high/very high cardiovascular risk. Consensus document of the Sociedad Española de Cardiología [Spanish Society of Cardiology] and the Sociedad Española de Diabetes [Spanish Diabetes Society].. Endocrinologia Diabetes y Nutricion. 2023; 70(Suppl.1)DOI:10.1016/j.endien.2022.11.009. PMID:36402735. IF:1.800(Q3/8D).
01/03/2023
Upadacitinib for Patients with Rheumatoid Arthritis: A Comprehensive Review
Sanmarti, R, Corominas, H. Upadacitinib for Patients with Rheumatoid Arthritis: A Comprehensive Review. Journal of Clinical Medicine. 2023; 12(5)DOI:10.3390/jcm12051734. PMID:36902522. IF:3.000(Q1/2D).
01/03/2023
Perception of survival/laryngeal preservation trade-off in advanced T-stage laryngeal cancer
Laccourreye, O, Mirghani, H, Guiquerro, S, Quer, M, Giraud, P. Perception of survival/laryngeal preservation trade-off in advanced T-stage laryngeal cancer. European Annals of Otorhinolaryngology-Head and Neck Diseases. 2023; 140(2)DOI:10.1016/j.anorl.2022.12.008. PMID:36642664. IF:1.900(Q2/3D).
01/03/2023
Clinical and endoscopic outcomes of patients with colonic Crohn's disease treated with 5-aminosalicylates as monotherapy
Castillo-Regalado E., Ríos R., Aràjol C., Gely C., Márquez L., Calafat M., González-Muñoza C., Cañete F., Mesonero F., Guardiola J., Garcia-Planella E., Mañosa M., Domènech E.. Clinical and endoscopic outcomes of patients with colonic Crohn's disease treated with 5-aminosalicylates as monotherapy. Gastroenterologia y Hepatologia. 2023; 46(3)DOI:10.1016/j.gastrohep.2022.09.003. PMID:36179946. IF:2.200(Q3/6D).
01/03/2023
Long-term Recurrence and Progression Patterns in a Contemporary Series of Patients with Carcinoma In Situ of the Bladder With or Without Associated Ta/T1 Disease Treated with Bacillus Calmette-Guérin: Implications for Risk-adapted Follow-up
Subiela J.D., Rodríguez Faba Ó., Aumatell J., Gonzalez-Padilla D.A., Rosales Bordes A., Huguet J., Krajewski W., Algaba F., López Curtis D., Brasero Burgos J., Sánchez González Á., Jiménez Cidre M.Á., Burgos Revilla F.J., Breda A., Palou J.. Long-term Recurrence and Progression Patterns in a Contemporary Series of Patients with Carcinoma In Situ of the Bladder With or Without Associated Ta/T1 Disease Treated with Bacillus Calmette-Guérin: Implications for Risk-adapted Follow-up. European Urology Focus. 2023; 9(2)DOI:10.1016/j.euf.2022.09.007. PMID:36163105. IF:4.900(Q1/2D).